Anavex Life Sciences Corp (AVXL)

[falconer66a]

Please tell, how is this Anavex negative?

A very common S1 agonist research compound was used,...

...and it caused Alzheimer’s problems.

Ok, then, give us your (detailed) take on what the paper revealed, as it relates to the Anavex mechanism of action (MOA) on the sigma-1 receptor agonist. Without those details, you seem to imply that blarcamesine, too, must fail.

Did the paper show that certain sigma-1 receptor agonists (such as the one in the study) do, indeed, disrupt normal sigma-1 receptor function and cause increased production of amyloid wastes, thereby causing Alzheimer’s symptoms?

If so, how might that negate the findings (also in mice) that blarcamesine favorably modulates sigma-1 receptor functions, thereby reducing Alzheimer’s symptoms?

The referenced murine research shows that PRE-084 causes Alzheimer’s problems. Blarcamesine suppresses, eliminates, or prevents them. If the PRE-084 murine results are predictive for blarcamesine, it certainly would be wise to liquidate an AVXL position. It’s predicated on the anticipated human clinical results in the Rett syndrome, Parkinson’s disease dementia, and Alzheimer’s clinical studies coming to an end, allowing the FDA to approve blarcamesine for treatments of the three CNS diseases.

Those who wish to believe that the failure of PRE-084 to stop Alzheimer’s problems in mice means that blarcamesine, too, will fail in humans may need to re-evaluate any AVXL position they hold. The rest of us; we’ll being holding until the clinical results appear. Based on real studies in both mice and men (well, women, too), we are confident in how the clinical trials will resolve.